The drugs at the top of the 2013 patent expiry list are shown in Table 1. The most lucrative targets for generics manufacturers are expected to be Eli Lilly’s anxiety and depression drug Cymbalta (duloxetine) and Biogen Idec’s multiple sclerosis biological Avonex (interferon beta-1a).

Table 1: Top patent losses during 2013

Two major biologicals Neupogen (filgrastim) and Procrit (epoetin alpha) will both lose their patent protection in the US in 2013, but the lack of practical guidance from FDA may slow the entry of biosimilars to the US market. These two biologicals have already lost patent protection in Europe, where biosimilars for epoetin alpha and filgrastim were already introduced in 2007 and 2008, respectively [1].

Related articles

Patent cliff winners and losers

2013’s biggest patent expiries

2012’s biggest patent expiries

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 17]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.